NCT06643884 Suprachoroidal Administration in Subjects With Metastases to the Choroid
| NCT ID | NCT06643884 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Aura Biosciences |
| Condition | Eye Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2024-12-16 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 24 participants in total. It began in 2024-12-16 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Eligibility Criteria
Inclusion Criteria: * Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor. * Have at least one Metastases to the Choroid in the study eye Exclusion Criteria: * Active ocular infection or disease. * Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment. * Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
Contact & Investigator
Medical Monitor
STUDY DIRECTOR
Aura Biosciences
Frequently Asked Questions
Who can join the NCT06643884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Eye Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06643884 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06643884 currently recruiting?
Yes, NCT06643884 is actively recruiting participants. Contact the research team at clinical@aurabiosciences.com for enrollment information.
Where is the NCT06643884 trial being conducted?
This trial is being conducted at Palo Alto, United States, Miami, United States, Boston, United States, Ann Arbor, United States and 6 additional locations.
Who is sponsoring the NCT06643884 clinical trial?
NCT06643884 is sponsored by Aura Biosciences. The principal investigator is Medical Monitor at Aura Biosciences. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.